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ABSTRACT 
 
Temozolomide (TMZ) is an alkylating chemotherapeutic agent that prolongs the 
survival of patients with glioblastoma. Clinical benefit is more prominent in patients 
with methylation of the O6-methyl-guanine DNA methyltransferase (MGMT) promoter. 
However, all patients eventually suffer from tumor progression because their tumors 
become resistant to TMZ. Here, we modelled acquired TMZ resistance in glioma cells 
in vitro to identify underlying molecular mechanisms. To this end, the glioma cell lines 
LNT-229, LN-308 and LN-18 were exposed repetitively to increasing concentrations 
of TMZ to induce a stable resistant phenotype (R) defined by clonogenic survival 
assays. The molecular mechanisms mediating acquired resistance were assessed by 
immunoblot, PCR and flow cytometry. Rescue experiments were performed with 
siRNA-mediated candidate gene silencing. We found in LN-18 cells constitutively 
expressing MGMT a strong up-regulation of MGMT levels in TMZ-resistant cells. 
TMZ resistance in the MGMT-negative cell lines LNT-229 and LN-308 was not 
associated with de novo expression of MGMT. Instead, we found a down-regulation 
of several DNA mismatch-repair proteins in resistant LNT-229 cells. A TMZ-resistant 
phenotype was also achieved by silencing selected DNA mismatch repair proteins in 
parental LNT-229 cells. No obvious mechanism of resistance was identified in the 
third cell line, LN-308, except for reduced methylation of LINE-1 repetitive elements. 
In conclusion, we demonstrate that different molecular mechanisms may contribute to 
the development of acquired TMZ resistance in glioma cells, indicating the need to 
develop distinct strategies to overcome resistance.  
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Abbreviations 
Anx, annexin; APNG, alkylpurine-N-glykosylase; ATM, Ataxia Telangiectasia Mutated 
protein; ATR, Ataxia Telangiectasia and Rad3-related protein; DMEM, Dulbecco’s 
modified Eagle’s medium; DMSO, dimethylsulfoxide; ECL, enhanced 
chemoluminescence; FCS, fetal calf serum; fwd, forward; HRP, horseradish 
peroxidase; MGMT, O6-methyl-guanine DNA methyltransferase; MLH1, MutL 
homolog 1; MMR, mismatch repair; MSH, MutS homolog; MSP, methylation-specific 
polymerase chain reaction; O6-BG: O6-benzylguanine; PI, propidium iodide; PMS1, 
postmeiotic segregation increased, S. cerevisiae 1; rv, reverse; TMZ, temozolomide; 
TSA, trichostatin A. 
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INTRODUCTION 
 
Despite recent therapeutic advances, the prognosis of patients afflicted by 
glioblastoma remains poor, with a progression-free survival in the range of months, 
even with multimodal therapy including surgery, radio- and chemotherapy. 
Temozolomide (TMZ), an oral alkylating agent, has demonstrated activity against 
recurrent and newly diagnosed glioblastoma and is being used as the standard of 
care since 2000 respectively 2005 (Yung et al. 2000, Stupp et al. 2005). 
The DNA repair protein O6-methylguanine methyltransferase (MGMT) removes O6-
alkyl-guanine adducts from DNA through irreversible binding and degradation, 
thereby minimizing the DNA-damaging effects of alkylating agent chemotherapy 
(Wang et al. 1996, Phillips et al. 1997). Accordingly, pharmacological inhibition of 
MGMT promotes antitumor activity of alkylating agents such as TMZ both in vitro and 
in vivo (Dolan et al. 1991, Wedge et al. 1996). Epigenetic silencing of the MGMT 
gene in tumor cells by methylation of its promoter had been associated with glioma 
sensitivity to alkylating chemotherapy (Esteller et al. 2000) and has been identified as 
a predictive biomarker for benefit from TMZ in patients with newly diagnosed 
glioblastoma (Hegi et al. 2005, Weller et al. 2010).  
However, even patients with initial tumor control will inevitably relapse or progress 
during or after TMZ therapy. Thus, both constitutive and acquired glioma cell 
resistance to alkylating chemotherapy are major clinical challenges. A better 
understanding of the underlying mechanisms may allow for a more durable benefit 
from the anti-glioma properties of TMZ. 
In contrast to its role in primary chemoresistance, the role of MGMT in acquired 
resistance to TMZ has only partially been assessed. Few, if any, patients exhibit a 
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change of MGMT promoter methylation status at progression (Brandes et al. 2010, 
Christmann et al. 2010, Felsberg et al. 2011). 
Another DNA repair system that has been proposed to mediate chemoresistance in 
various tumor cells is the DNA mismatch repair (MMR) system, which consists of 
several enzymes. The role of deficient MMR has been addressed in most detail in 
colon cancer. Here, MMR mutations cause genetic predisposition associated with an 
increased risk for colon cancer (Bronner et al. 1994, Papadopoulos et al. 1994). The 
MMR system recognizes and repairs base mismatches after DNA replication, mostly 
mediated by two heterodimers of MutS homologues, MutS-α (MSH2/MSH6 
heterodimer) for small insertion/deletion loops and MutS-β (MSH2/MSH3 
heterodimer) for large insertion/deletion loops (Genschel et al. 1998). Colon 
carcinoma cells are up to 60x more resistant to alkylating agent chemotherapy when 
the MMR genes are mutated (Liu et al. 1996). 
In human gliomas, the expression of 6 MMR proteins has been detected. Their role 
has not been well elucidated yet. While some reports postulate that an 
overexpression of MMR proteins exerts oncogenic effects, most probably by 
continuous DNA repair promoting survival (Rellecke et al. 2004), other authors have 
shown that a defective MMR system may favor tumor growth and chemoresistance. It 
is assumed that a lack of correct DNA replication leads to an accumulation of DNA 
damage and subsequent tumor growth (Yip et al. 2009).  
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MATERIALS AND METHODS 
 
Materials and cell lines 
All glioma cell lines were kindly provided by Dr. N. de Tribolet (Lausanne, 
Switzerland). TMZ-resistant cells were generated by repetitive pulse exposure of 
LNT-229, LN-308 and LN-18 glioma cells to TMZ (24 h exposure every 2 weeks). 
Increasing concentrations of TMZ were applied over 6 months under consideration of 
the respective EC50 values (Hermisson et al. 2006), with selection and culturing of 
the resistant surviving cell fraction of each passage and consecutive re-exposure to a 
TMZ pulse after confluent growth. The derived resistant cell lines are further referred 
to as LNT-229_R, LN-308_R and LN-18_R. All cell lines were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% FCS, 2 mM glutamine and 
penicillin (100 IU/ml)/streptomycin (100 µg/ml). TMZ was provided by Schering-
Plough (Kenilworth, NJ, USA). A stock solution of TMZ at 50 mM was prepared in 
dimethylsulfoxide (DMSO) and stored at -20°C. Propidium iodide (PI), trichostatin A 
and all other reagents, unless indicated otherwise, were purchased from Sigma (St. 
Louis, MO, USA). 
 
Viability and clonogenic assays 
Proliferation was assessed by obtaining viable cell counts using trypan blue dye 
exclusion. For cytotoxicity assays, 5 x 103 cells were seeded per well in 96-well 
plates, allowed to attach for 24 h, and exposed to TMZ as indicated for 72 h in 
serum-free medium. Clonogenic assays were performed by seeding 102 cells for 
LNT-229 and LN-18 or 3 x 102 cells for LN-308 per well in 96-well plates. After 24 h, 
the cells were exposed to TMZ as indicated for 24 h in serum-free medium, followed 
 7 
by observation for 7-14 days in FCS-containing medium. For both assays, cell 
density was assessed by crystal violet staining of adherent cells.  
 
Immunoblot analyses  
The cells were treated with TMZ or DSMO vehicle and lysed in lysis buffer containing 
2 µg/ml Aprotinin, 10 µg/ml Leupeptin and 100 µg/ml PMSF (Sigma). Proteins (20 
µg/lane) were separated on 8-12% acrylamide gels. After transfer to nitrocellulose 
(Biorad, Munich, Germany), the blots were blocked in PBS containing 5% skim milk 
and 0.05% Tween 20 and incubated overnight at 4°C with primary antibodies and 1 h 
at room temperature for secondary antibodies. Visualization of protein bands was 
accomplished using horseradish peroxidase (HRP)-coupled secondary antibodies 
(Santa Cruz / Healthcare) and enhanced chemiluminescence (Pierce / Thermo 
Fisher, Madison, WI, USA) using a G:BOX imager (Syngene, Cambridge, UK). The 
following antibodies were used: anti-MGMT from Alpha Diagnostics (San Antonio, 
TX, USA), anti-p21 from BD Bioscience (Heidelberg, Germany), antibodies to p53 
MSH3 and alkylpurine-N-glykosylase (APNG) from Santa Cruz (Santa Cruz, CA, 
USA), PMS2, MSH6 and MLH1 antibodies from BD (Franklin Lakes, NJ, USA), 
antibody to MSH2 from Calbiochem/Merck (Darmstadt, Germany), anti-PMS1 from 
Abcam (Cambridge, UK), and anti-GAPDH from Everest Biotech (Oxfordshire, UK). 
For immunoblot analysis of histone modificatons, the cells were lysed in 250 µl cell 
lysis buffer (50 mM Tris HCL, pH=8, 150 mM NaCl, 0,5% Triton X-100, 0.5% 
deoxycholate) containing 1 x protease inhibitors (Roche GmbH, Ref.: 1183617001). 
Proteins (30 µg/lane) were separated on 15% acrylamide gels (Tricin-SDS PAGE). 
After transfer to nitrocellulose membranes (Whatman GmbH, Dassel), the blots were 
blocked in TBS containing 5% milk and 0.1% Tween 20 and incubated overnight at 
4°C with primary antibodies and 1 h at room temperature with horseradish 
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peroxidase (HRP)-coupled secondary antibodies (Pierce Technology, Rockford, IL; 
Thermo Fisher Scientific, Waltham, MA). Visualization of protein bands was 
performed by using ImmobilonTM Western HRP Substrate containing luminol and 
peroxide solution (Millipore, Billerica, MA). Chemiluminescence was recorded with 
the LAS-3000 mini imager (FUJIFILM Life Science, Stanford, CT). The following 
primary antibodies were used: anti-H3 (# 17-10046, 1:1000), anti-H3ac (# 06-599, 
1:10000) and anti-H3K9me3 (# 17-625, 1:1000) from Upstate (Charlotteville, VA), 
and anti-tubulin (# T9026, 1:3000) from Sigma-Aldrich GmbH (Steinheim, Germany) 
 
Quantitative reverse transcriptase PCR 
Total RNA from untreated cells or cells exposed to the respective agents, TMZ for 24 
h, TSA for 48 h, was prepared using the NucleoSpin System (Macherey-Nagel AG, 
Oensingen SO, Switzerland) and transcribed into cDNA according to standard 
protocols using random primer (Bioconcept/NEB, Bioconcept, Allschwil, Switzerland) 
and Superscript II reverse transcriptase (Invitrogen, CA, USA). For real-time PCR, 
cDNA amplification was monitored using SYBRGreen chemistry on the 7300 Real 
time PCR System (Applied Biosystems, Zug, Switzerland). The conditions for these 
PCR reactions were: 40 cycles, 95°C/15 sec, 60°C/1 min, using the following specific 
primers: GAPDH forward (fwd): 5'-CTCTCTGCTCCTCCTGTTCGAC-3', GAPDH 
reverse (rv): 5'-TGAGCGATGTGGCTCGGCT-3'; MGMT fwd: 5'-CAC TTC ACC ATC 
CCG TTT TCC-3’, MGMT rv: 5'-TGC TGG TAA GAA ATC ACT TCT CC-3’;  p21 fwd: 
5'-GAC CAG CAT GAC AGA TTT CTA CCA-3', p21 rv: 5'-TTC CTG TGG GCG GAT 
TAG G-3', MSH2 fwd: 5’-GCT GGA AAT AAG GCA TCC AAG G-3’, MSH2 rv: 5’-
CAC CAA TGG AAG CTG ACA TAT CA-3’; MSH3 fwd: 5’-TGG AAA ATG ATG GGC 
CTG TTA AA-3’, MSH3 rv: 5’-AGA CAT TCC CAG ATC ACT TCC T-3’; MSH6 fwd: 
5’-AGC TTA AAG GAT CAC GCC ATC-3’, MSH6 rv: 5’-AAG CAC ACA ATA GGC 
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TTT GCC-3’; PMS1 fwd: 5’-GTT CTG GGG ACT GCT GTT ATG-3’, PMS1 rv: 5’-
GGT CTG CAT CAC ACT TTG GAA-3’; PMS2 fwd: 5’-GAA GGT TGG AAC TCG 
ACT GAT G-3’, PMS2 rv: 5’-CGC ACA GGT AGT GTG GAA AA-3’; MLH1 fwd: 5’-
TTC GTG GCA GGG GTT ATT CG-3’, MLH1 rv: 5’-GCC TCC CTC TTT AAC AAT 
CAC TT-3’; ATM fwd: 5’-TTC CAT ACC TGA AGT GTA GCA TAA A-3’; ATM rv: 5’- 
AAT TTG CCA GTC TCA TTA ACC C-3’; ATR fwd: 5’- TCT CAG CCA ACC TCC 
GTG AT-3’; ATR rv: 5’- GCA GAA GTC TCG TTA TGA TCC AA-3’; cyclin D1 fwd: 5'-
GAA CAA ACA GAT CAT CCG CAA AC-3'; cyclin D1 rv: 5'-GCG GTA GTA GGA 
CAG GAA GTT G-3' ; p27 fwd: 5'-TAA TTG GGG CTC CGG CTA ACT-3'; p27 rv: 5'-
TTG CAG GTC GCT TCC TTA TTC-3'; APNG fwd: 5´- CCC ATA CCG CAG CAT 
CTA TT-3’; APNG rv: 5´- AGG TAT GCC TCG GTC TCC AC-3’. Data analysis was 
done using the ΔΔCT method for relative quantification. 
 
DNA mutation and methylation analyses 
For methylation-specific PCR (MSP) analysis of the MGMT promoter, 2 pairs of 
primers, each specific for either the methylated or the unmethylated promoter region, 
were used. Primer sequences for the unmethylated sequence were fwd: 5′-TTT GTG 
TTT TGA TGT TTG TAG GTT TTT GT-3′ and rv: 5′-AAC TCC ACA CTC TTC CAA 
AAA CAA AAC A-3′, and for the methylated sequence fwd: 5′-TTT CGA CGT TCG 
TAG GTT TTC GC-3′ and rv: 5′-GCA CTC TTC CGA AAA CGA AAC G-3′. The MSP 
reactions were prepared in a total volume of 25 µl using HotStarTaq® Master Mix Kit 
(Qiagen, Hilden, Germany). For PCR, 1.8 µl of bisulfite-modified DNA were added 
and subjected to 36 PCR cycles with denaturation at 94°C for 30 sec, primer 
annealing at 59°C for 40 sec, extension at 72°C for 2 min and a final extension for 10 
min. PCR products were separated using Spreadex® EL 600 or 800 gels (Elchrom 
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Scientific AG, Cham, Switzerland) and loaded with 3–5 µl of the respective PCR 
product. Electrophoresis was carried out at 120 V and 55°C for 40 min. Amplicons 
were visualized using SYBR® Gold (Molecular Probes, OR) (Felsberg et al. 2009). In 
addition, MGMT promoter methylation was assessed by DNA pyrosequencing as 
reported (Felsberg et al. 2011). 
Methylation analyses of the MLH1, MSH2, MSH6 and PMS2 gene promoters were 
assessed by DNA pyrosequencing as described (Felsberg et al. 2011). In addition, 
we investigated exons 1 to 10 of MSH6 for mutation using single-strand conformation 
polymorphism (SSCP) analysis followed by direct sequencing (Reifenberger et al. 
1996). The respective primer sequences are available on request. The methylation 
level of LINE-1 (GenBank accession number X58075) was also assessed by DNA 
pyrosequencing using the PyroMark LINE-1 kit (Qiagen, Hilden, Germany) and the 
PyroMark Q24 sequencer (Qiagen).  
 
Reporter assay 
Dual luciferase/renilla assays were carried out with co-transfection of 150 ng of the 
pGL2-Luc MGMT (575/+24ML) reporter construct and 20 ng of the renilla reniformis-
CMV (pRL-CMV) control plasmid (Promega, Madison, WI, USA). Luciferase activity 
was normalized to constitutive renilla activity. The pGL2-Luc MGMT (575/+24ML) 
construct (Biswas et al. 1999) was a kind gift from Dr. S. Mitra (Sealy Center for 
Molecular Science and Department of Human Biological Chemistry and Genetics, 
University of Texas Medical Branch, Galveston, TX, USA).  
 
Flow cytometry 
For cell cycle analysis, LNT-229, LN-308 and LN-18 parental or resistant (R) cells 
were treated with TMZ or transfected with siRNA 24 h before analysis as indicated 
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below, harvested, fixed and permeabilized overnight in ice-cold 70% ethanol (Fluka 
/Sigma Aldrich Buchs, Switzerland). After washing with PBS, RNA was digested with 
RNase A (Carl Roth AG, Karlsruhe, Germany). DNA was stained with PI (50 µg/ml) 
and fluorescence was recorded in a CyAn ADP S2536 analyzer (Dako Cytomation, 
Carpinteria, CA). For analysis of cell death, cells were grown in six-well plates, 
incubated with TMZ at different concentrations for 24 h, washed in PBS and allowed 
to grow for 72 h. Annexin (Anx) V-fluorescein isothiocyanate (1:100) and PI (50 
µg/ml) were added, and fluorescence in a total of 10,000 events per condition was 
recorded in a CyAn flow cytometer. AnxV-fluorescein isothiocyanate- or PI-positive 
cells were counted as dead cells, and the remaining cells were designated the 
surviving cell fraction. 
 
RNA interference-mediated gene silencing 
For transient transfections, 2.5 × 105 glioma cells were seeded in a six-well plate and 
exposed to 100 nmol/L of either specific or scrambled control small interfering 
(si)RNA, using Metafectene Transfection reagent (Biontex Laboratories GmbH, 
Martinsried, Germany) for 12 h. siRNA was purchased from Microsynth AG (Balgach, 
Switzerland). Cell pellets for FACS analysis were collected 24 h after transfection; 
RNA samples were collected 48 h after the first exposure to the siRNA; protein 
samples were collected 72 h post transfection. The following sequences were used: 
MSH2: 5’-GUC CAA GGU GAA ACA AAU GTT-3’; MSH3: 5’-CCA AAU AAC UAG 
AGG AAU UTT-3’; MSH6: 5’-CCU GAA AUA CUG AGA GCA ATT-3’; PMS1: 5’-GCG 
AAU GGU UUC AAG AUA ATT-3’; PMS2: 5’-CAA UGU UAC UCC AGA UAA ATT-3’; 
MLH1: 5’-GGA AGA UUC UGA UGU GGA ATT-3’; p21: 5’-GGA CAG CAG AGG 
AAG ACC ATT-3’. 
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Data analysis  
Data are representative of experiments performed three times with similar results. 
Viability and proliferation studies were performed using triplicate wells. Where 
indicated, analysis of significance was performed using the two-tailed Student’s t-test. 
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RESULTS 
 
Repeated exposure to TMZ induces resistance in human glioma cells  
LNT-229, LN-308 and LN-18 glioma cells were pulse-exposed to increasing 
concentrations of TMZ for 6 months until a stable resistant phenotype was observed. 
No change in cellular morphology was observed by light microscopy (Supplementary 
Figure 1). All resistant sublines (R) showed reduced proliferation compared with the 
parental lines although their baseline cell cycle distribution was unaltered. No 
differences between the cell lines could be identified in Annexin/PI-FACS, either 
(Supplementary Figure 2). Acute growth inhibition and clonogenic survival assays 
were used to characterize the sensitivity of these cells to TMZ. Parental cells without 
prior exposure to TMZ or the TMZ-pre-exposed glioma cells were exposed to 
increasing concentrations of TMZ. We noticed an up to 10-fold increase of the EC50 
values in the resistant sublines in clonogenic assays (Figure 1A). In both paradigms, 
TMZ led to a concentration-dependent decrease of viable cell counts in all cell lines 
examined. LNT-229_R, LN-308_R and LN-18_R cells displayed reduced sensitivity to 
TMZ compared with parental cells in acute survival (Figure 1B) and clonogenic 
assays (Figure 1C). All resistant cell lines exhibited resistance features for at least 
more than 1 year after the last exposure to TMZ (Supplementary Figure 3). This 
induction of resistance was restricted to TMZ in LNT-229_R or LN-308_R cell lines 
that showed no cross-resistance to lomustine (CCNU), while there was cross-
resistance in LN-18_R cells. No cross-resistance was observed for cytarabine in any 
cell line (Supplementary Figure 4). All further experiments were conducted under 
conditions mimicking the clonogenic cell death assays because clinically relevant 
concentrations of TMZ, which are in the range of 50-70 µM, are active in these 
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assays only, consistent with the observation that MGMT mediates resistance to TMZ 
only in these assays (Hermisson et al. 2006). 
 
Up-regulation of MGMT contributes to acquired TMZ resistance in LN-18_R 
cells 
The expression of MGMT predicts the sensitivity of the glioma cell lines used here to 
TMZ: in contrast to LNT-229 and LN-308 glioma cells, which exhibit strong MGMT 
promoter methylation with more than 90% of methylated alleles revealed by DNA 
pyrosequencing, LN-18 cells lack MGMT promoter methylation, constitutively express 
MGMT and are the most resistant cells examined here (Hermisson et al. 2006) 
(Figure 1A). No change in the methylation status was observed in the resistant LNT-
229_R or LN-308_R cells compared with the respective parental cells (Figure 2A). 
Accordingly, no MGMT protein was demonstrated by immunoblotting in LNT-229_R 
and LN-308_R cells. In contrast, real-time PCR and immunoblotting revealed a 
strong increase in MGMT protein, mRNA and transcriptional activity levels in LN-
18_R cells compared with LN-18 parental cells (Figure 2A). 
MGMT is consumed in response to DNA damage by proteasomal degradation after 
removal of an alkyl group from the DNA (Srivenugopal et al. 1996). Both parental LN-
18 and LN-18_R cells displayed a concentration-dependent loss of MGMT protein 
levels after exposure to TMZ. However, LN-18_R cells still retained MGMT levels 
after exposure to TMZ at 1000 µM that were similar to untreated parental cells 
(Figure 2B).  
We next asked whether increased MGMT expression was responsible for induced 
TMZ resistance in LN-18_R cells. To this end, the cells were pretreated with the 
MGMT-depleting agent O6-BG prior to the TMZ challenge. An exposure to O6-BG for 
2 h before administration of TMZ depleted MGMT from both LN-18 and LN-18_R 
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cells (Figure 2C) and largely restored TMZ sensitivity of LN-18_R cells in clonogenic 
survival assays (Figure 2D). The EC50 shift induced by O6-BG was 3.1 in parental 
cells and 6.4 in resistant cells and thus more prominent in LN-18_R cells, 
corresponding to the contribution of increased MGMT levels to acquired resistance in 
this cell line. Thus, up-regulation of MGMT expression was identified as a mediator of 
resistance in one of the three cell lines examined here. 
 
TMZ-resistant glioma cells display differential changes in cell cycle 
progression in response to TMZ 
In order to further elucidate mechanisms underlying acquired TMZ resistance, we 
investigated cell cycle progression and the expression of cell cycle-related proteins in 
response to TMZ. In LNT-229 and LN-308 parental cells, exposure to TMZ induced a 
G2/M arrest in a concentration-dependent manner. In contrast, the resistant lines did 
not display any relevant change in cell cycle distribution. In parental LN-18 cells, TMZ 
induced acute cell death in a concentration-dependent manner, a finding that was 
much less prominent in LN-18_R cells. In contrast, the resistant LN-18 cells 
accumulated in G2/M (Figure 3A). This observation was confirmed by anxV/PI 
stainings which demonstrated an increase of the apoptotic fraction in LN-18 cells in 
response to TMZ that decreased to less than half in LN-18_R cells (Figure 3B). Thus, 
G2/M arrest was associated with prevention of growth in LNT-229 and LN-308 cells, 
but linked to clonogenic survival in LN-18 cells. 
 
p21 displays altered expression in resistant LN-18_R cells  
p21 is one of the major regulators of the cell cycle and has previously been linked to 
resistance to apoptosis in glioma cells (Naumann et al. 1998, Glaser et al. 2001). 
Real-time PCR and immunoblot revealed elevated p21 mRNA and protein levels in 
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untreated LN-18_R, but not in LNT-229_R or LN-308_R cells (Figure 4A, B). 
Moreover, exposure to TMZ strongly up-regulated p21 mRNA levels in LN-18_R cells 
(Figure 4C), but not in LNT-229_R or LN-308_R (data not shown). Accordingly, the 
doubling time in LN-18_R cells was distinctively reduced (Supplementary Figure 2). 
In contrast to p21, no significant changes were observed for ATM, ATR, p27 or cyclin 
D in either cell line (Supplementary Figure 5). Since LN-18 cells express a mutant 
p53 protein (Wischhusen et al. 2003), the induction of p21 expression is independent 
of p53. We also considered the possibility that the increased p21 levels were 
responsible for slowed cell cycle progression in LN-18-R cells. Accordingly, we 
silenced p21 expression in LN-18 or LN-18-R cells using siRNA. Interestingly, the 
main effect of silencing p21 was the acute induction of cell death rather than an 
altered cell cycle distribution, and the extent of cell death induction was more 
prominent in LN-18-R cells which expressed more p21 (37.5% versus 24.2%) 
(Supplementary Figure 6). Thus, a role for p21 specifically in cell cycle progression 
could not be confirmed. 
 
MMR protein down-regulation is important for TMZ-resistance in LNT-229-R 
Reduced levels of MMR proteins may promote resistance to alkylating agents, but 
their role in gliomas has remained controversial. While no significant changes in the 
mRNA expression and protein levels of MLH1, MSH2, MSH3, MSH6, PMS1 and 
PMS2 were observed in LN-308_R and LN-18_R cells (Supplementary Figure 7), 
real-time PCR and immunoblot analysis revealed reduced expression of all MMR 
molecules in LNT-229-R cells (Figure 5A, B). Reduced MMR protein levels were not 
a consequence of aberrant promoter methylation of MLH1, MSH2, MSH6 and PMS2 
as assessed by DNA pyrosequencing (data not shown). SSCP analysis of exons 1 to 
10 of MSH6 revealed no sequence differences in LN-18_R and LNT-229_R 
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compared with their respective parental cells. LN-308_R demonstrated an intronic 
point mutation c.412+5C>T which was not detected in the parental LN-308 cells and 
likely restricted to a subpopulation of cells (Supplementary Figure 8). However, this 
mutation is not directly affecting the intronic splice site and did not result in aberrantly 
spliced MSH6 transcripts as determined by RT-PCR. Thus, its functional role remains 
unclear. The functional consequences of reduced MMR protein levels for TMZ 
sensitivity were assessed by siRNA-mediated silencing of individual MMR genes in 
LNT-229 cells (Figure 5C). Down-regulation of MSH2, MSH6 or PMS2 by RNA 
interference led to reduced sensitivity to TMZ as assessed in clonogenic survival 
assays. No significant increase in resistance to TMZ was observed in LNT-229 cells 
after silencing of MSH3, PMS1 or MLH1.  
 
Acquired resistance to TMZ changes chromatin organization in LNT-229 cells 
It has been reported that TMZ induces heterochromatin reorganization in glioma cells 
(Papait et al. 2009). Heterochromatin is characterized by lower levels of acetylated 
core histones and higher levels of methylated histones, e.g., trimethylated H3K9. 
Immunoblots of parental and TMZ-resistant glioma cell lines revealed lower levels of 
acetylated H3 histones but higher levels of H3K9 trimethylated histones in resistant 
as opposed to parental LNT-229_R cells (Figure 6A), suggesting that a shift from a 
more euchromatin- to a more heterochromatin-centered status might contribute to the 
aquired TMZ resistance in this cell line, e.g. by altering gene expression. No such 
changes in histone H3 acetylation or H3K9 trimethylation were detected in the two 
other cell lines. Yet, altered histone acetylation does not account for the differential 
expression of MSH2, MSH6 and PMS2 proteins in LNT-229_R, since no change of 
mRNA expression levels was observed in LNT-229_R after exposure to the histone 
deacetylase (HDAC) inhibitor TSA (Supplementary Figure 9). 
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Decreased global DNA methylation levels indicated by LINE-1 methylation in 
LN-308_R and LN-18_R cells 
Long interspersed nuclear element-1 (LINE-1) is a human retrotransposon that has 
been proposed to create DNA double-strand breaks with genome-destabilizing 
effects and may be associated with G2/M arrest in cancer cells (Gasior et al. 2006, 
Belgnaoui et al. 2006). In most normal cells, LINE-1 sequences are silenced by 
methylation, whereas in cancer cells, LINE-1 may be overexpressed (Asch et al. 
1996, Bratthauer & Fanning 1992). Since LINE-1 accounts for approximately 18% of 
the human genome, its methylation status represents a surrogate indicator of global 
DNA methylation. Recent data suggested the LINE-1 methylation status as a better 
prognostic marker in glioblastoma patients than the MGMT promoter methylation 
status (Ohka et al. 2011). We investigated whether the methylation levels of LINE-1 
differ between parental and TMZ-resistant glioma cells. We found a significant 
reduction of methylation in resistant LN-308_R and LN-18_R cells relative to the 
respective parental cells, suggesting that reduced global DNA methylation may be 
involved in the acquired resistance to TMZ (Figure 6B). 
 
Alkylpurine–DNA–N-glycosylase (APNG) levels are not induced in resistant 
glioma cell lines 
APNG is an enzyme that repairs the cytotoxic lesions N3-methyladenine and N7-
methylguanine, and may contribute to TMZ resistance in glioblastoma (Agnihotri et al. 
2012). Accordingly, we performed PCR and immunoblot analyses to measure APNG 
levels, but found these to be unaltered in the resistant as compared to the 
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corresponding parental glioma lines (Supplementary Figure 10), indicating that APNG 
does not play a modulating role in acquired TMZ-resistance in our cell line models. 
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DISCUSSION 
Responsiveness to cytotoxic therapies defined by radiological responses or at least 
radiologically defined stable disease is commonly of short duration in malignant 
glioma patients. This is also true for many patients expected to derive benefit from 
alkylating agent chemotherapies because of MGMT promoter methylation (Hegi et al. 
2005, Weller et al. 2010). The mechanisms leading to acquired resistance to TMZ are 
incompletely understood. Here, we generated TMZ–resistant glioma cell lines by 
repetitive exposure to increasing TMZ concentrations. Although this approach may 
not closely reflect the situation in vivo, it allows for an assessment of mechanisms 
triggered by repeated pulse exposure to TMZ. 
First, we demonstrated that TMZ resistance can be induced in different glioma cell 
lines, independently of the MGMT promoter methylation status: the EC50 values 
increased up to 10-fold in resistant cells (Figure 1). Given the prominent role of 
MGMT in determining sensitivity to alkylating agent chemotherapy, it would be 
tempting to speculate that resistant subclones generated from MGMT promoter-
methylated cell lines exhibit a loss of promoter methylation and de novo expression 
of MGMT. Yet, this was not the case (Figure 2A), consistent with the analysis of 
paired recurrent and primary tumor specimens in vivo which confirmed a stable 
MGMT status at recurrence in the vast majority of patients (Felsberg et al. 2011). We 
also investigated whether constitutively MGMT-positive LN-18 cells exhibit changes 
in MGMT levels when induced to become even more TMZ-resistant. Since MGMT is 
consumed when counteracting TMZ-induced DNA damage, the intracellular levels of 
MGMT are predicted to correlate with chemoresistance. In fact, we found a striking 
increase in MGMT mRNA and protein in TMZ-resistant LN-18 cells. Not surprisingly, 
LN-18_R cells exhibited cross-resistance to another alkylator, lomustine, which was 
not found in the MGMT-negative resistant cells that had developed MGMT-
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independent pathways of resistance (Supplementary Figure 4). Immunoblot analyses 
revealed that MGMT levels were increased to a quantity high enough in resistant LN-
18_R to still have similar levels of MGMT after exposure to 1000 µM TMZ as 
untreated parental cells (Figure 2B). Considering that the median serum 
concentration measured in patients treated with TMZ at 150 mg/m2 in clinical settings 
corresponds to 50 µM (Hammond et al. 1999), it becomes clear how this gain in 
MGMT levels may confer acquired resistance. Depletion of MGMT with O6-BG largely 
restored TMZ sensitivity although the resistance of LN-18_R remained slightly above 
that of parental cells, underlining that chemoresistance is multimodal and involves 
more than one pathway. One additional mechanism operating in LN-18_R cells 
identified here is an induction of p21, a key regulator of cell cycle progression (Fig. 4) 
previously linked to apoptosis resistance in glioma cells (Naumann et al. 1998, 
Glaser et al. 2001). Admittedly, even with O6-BG, the concentrations required to 
inhibit LN-18 growth in vitro exceeded the TMZ concentrations achieved in vivo, 
suggesting that the study of primarily MGMT promoter-methylated cell lines such as 
LNT-229 and LN-308 acquiring resistance is the more relevant paradigm. 
It has been previously reported that exposure to TMZ induces cell cycle arrest rather 
than cell death in glioma cells (Hirose et al. 2001). We noted distinct changes in the 
cell cycle responses to TMZ upon induction of TMZ resistance: in LNT-229_R and 
LN-308_R cells, the G2/M arrest induced by TMZ was abrogated and altered into 
continuous cellular growth. Interestingly, LN-18 cells, although relatively 
chemoresistant, underwent cell death rather than cell cycle arrest when treated with 
TMZ, albeit at concentrations exceeding the clinically relevant range. Here, resistant 
LN-18_R cells counteracted this effect by entering G2/M cell cycle arrest, staying in a 
quiescent status instead of undergoing apoptotic cell death. The major candidate 
mediator for this evasive mechanism was identified here as increased constitutive 
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expression and superinduction by TMZ of p21, a negative modulator of cell cycle 
progression that may lead to G1-, G2- or S-phase arrest (Ogryzko et al. 1997). In 
resistant LN-18_R cells, p21 was overexpressed up to 5-fold, likely accounting for 
cell cycle slowing and escape from cell death, and matching the observed slower 
growth of resistant LN-18_R in culture in proliferation assays (Supplementary Figure 
2). An even more distinct increase in p21 mRNA levels was seen in LN-18_R when 
exposed to TMZ, corroborating the role of this cyclin-dependent kinase inhibitor for 
cell survival in resistant LN-18_R cells. These results are consistent with an increase 
in p21 levels as a resistance mechanism leading to a G2 arrest without induction of 
apoptosis in glioma cells after p53 gene transfer (Gomez-Manzano et al. 1997). 
After having ruled out that demethylation of the MGMT promoter accounted for 
acquired resistance in the MGMT promoter-methylated cell lines, we investigated 
whether MMR protein levels varied between parental and resistant cells. To date, 
literature on MMR in glioma has remained inconsistent. While some findings indicate 
a role for cellular resistance being associated with MMR deregulation (Yip et al. 
2009), others reported no significant impact of MMR on resistance (Maxwell et al. 
2008). Here, we found that, while no significant change in MMR levels was found in 
LN-18_R or LN-308_R cells (Supplementary Figure 7), LNT-229_R exhibited a strong 
down-regulation of all 6 investigated MMR proteins in TMZ-resistant cells. 
Experiments with siRNA-mediated knockdown proved that MMR gene silencing 
mediates resistance to TMZ in LNT-229 parental cells for MSH2, MSH6 and PMS2, 
all of them involved in the formation and heterodimerization of the α-subunit of MutS 
and MutL, respectively, both more relevant for base repair than the β-subunit. This is 
in accordance with former investigations on colon carcinoma cells where TMZ 
resistance increased in MMR-deficient cells (Liu et al. 1996). Most importantly, a 
single protein knockdown transiently around the time of the TMZ application was 
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sufficient to induce resistance in formerly sensitive cells. Interestingly, these data are 
consistent with recent findings of reduced MMR protein levels in patient tissue from 
glioblastoma at recurrence, identifying the same 3 MMR proteins, MSH2, MSH6 and 
PMS2, as being significantly down-regulated in patients at tumor recurrence 
(Felsberg et al. 2011). Acquired methylation of the respective MMR gene promoters 
does not account for the reduced expression of MMR mRNA and protein as 
investigated by methylation-specific PCR in our cell lines as well as in primary and 
recurrent glioblastoma primary tissues (Felsberg et al. 2011). Moreover, using TSA 
treatment, we also detected no evidence that altered histone acetylation contributes 
to the observed down-regulation of MMR genes in LNT-229_R, albeit these cells 
displayed a globally reduced acetylation and increased methylation of histone H3. 
The latter finding may point to a role of epigenetic gene regulation in the acquired 
TMZ resistance of this cell line, however, the potentially affected genes need to be 
identified.  
None of the above-mentioned resistance mechanisms appeared to be operating in 
LN-308 cells. We found a potential role for reduced methylation of LINE-1 sequences 
in LN-308_R and LN-18_R cells, suggesting reduced global DNA methylation that 
might lead to reduced DNA stability as a probable resistance mechanism. In LN-
18_R, this effect could contribute to the cell cycle slowing and G2/M arrest. 
Collectively, our results suggest that acquired resistance to TMZ in glioma cells is not 
mediated through a single pathway, but that multiple mechanisms may contribute to 
this phenotype in different cell lines. It will be crucial for adjusted therapy to get a 
better understanding of all the involved pathways to allow for a personalized relapse 
therapy once the tumor developed resistance. 
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FIGURE LEGENDS 
 
Figure 1. Repeated exposure to TMZ induces resistance in human glioma cells. 
A. LNT-229, LN-308 or LN-18 glioma cells were exposed to increasing 
concentrations of TMZ to induce acquired resistance as described in the Materials 
and Methods section. EC50 values were calculated for parental (black) and resistant 
(white) cell lines. B, C. Parental (black diamonds) or resistant (open squares) cells 
were exposed to increasing concentrations of TMZ for 72 h in serum free medium 
(acute growth inhibition assay, B) or for 24 h and allowed to grow 2-3 weeks in 
complete medium (clonogenic cell death assay, C). Cell density was assessed by 
crystal violet staining. Data were assessed in triplets; representative diagram 
(*p<0.05, **p<0.01, ***p<0.001, t-test). 
 
Figure 2. Acquired TMZ resistance in LN-18 cells is associated with increased 
MGMT expression. A. Specific primer sets were used to differentiate between 
methylated (M) and unmethylated (U) MGMT promoter sequences in parental and 
resistant glioma cells. U= unmethylated; M= methylated. A172 glioma cells served as 
a control for methylated sequences, peripheral blood mononuclear cells (PBMC) as a 
control for unmethylated sequences (upper panel). Whole cell lysates of parental and 
resistant glioma cells were assessed by immunoblot for MGMT protein levels (lower 
panel). GAPDH was used as a control. MGMT mRNA expression was examined by 
real-time PCR. LN-18/LN-18_R cells were transiently transfected with pGL2-Luc 
MGMT (575/+24ML) and pRL-CMV. Reporter activity is presented in RLU units 
(**p<0.01 compared to parental LN-18, t-test). B. LN-18 or LN-18_R cells were 
exposed to TMZ for 24 h and allowed to recover in complete medium for 72 h. MGMT 
levels were determined as in (A). C. LN-18 or LN-18_R cells were pretreated for 2 h 
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with O6-BG (50 µM) and subsequently exposed to TMZ. MGMT levels were 
determined by immunoblot at 72 h. D. Glioma cells were pretreated with O6-BG (50 
µM) for 2 h, exposed to TMZ for 24 h, and assessed for clonogenic survival (parental 
LN-18 without O6-BG: open diamonds; parental LN-18 + O6-BG: black diamonds; LN-
18_R without O6-BG: open squares; LN-18_R, + O6-BG: black squares).  
 
Figure 3. TMZ-resistant glioma cells display different patterns of cell cycle 
changes in response to TMZ. A. Parental (left) and resistant (right) cells were 
exposed to TMZ for 24 h, cultured for an additional 48 h in serum-enriched medium, 
fixed, permeabilized, stained with PI and analyzed by flow cytometry. Cell distribution 
is shown as bar graphs (striped: sub-G1, black: G1, white: S, grey: G2/M). B. 
Annexin-FACS was performed in LN-18/LN-18_R cells to confirm apoptotic cell death 
(white: anxV/PI-negative, black: anxV-positive, grey: PI-positive, checked: anxV/PI-
positive). 
 
Figure 4. p21 is differentially expressed in LN-18-R cells. A. p21 mRNA 
expression was assessed by real-time PCR in TMZ-resistant cells (***p<0.001). B. 
Whole cell lysates of LN-18 and LN18_R cells were assessed for p21 protein by 
immunoblot. GAPDH was used as a reference. C. LN-18 or LN-18_R cells were 
exposed to TMZ for 24 h and cultured for an additional 24 h in serum-enriched 
medium prior to RNA extraction. p21 mRNA expression was subsequently assessed 
by real-time PCR in duplicate (*p<0.05, effect of TMZ, +*p<0.05, effect of R 
phenotype). 
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Figure 5. Acquired TMZ resistance in LNT-229 cells is associated with 
decreased MMR protein levels. A. The mRNA expression of MMR family members 
was assessed by real-time-PCR. B. MMR protein levels were assessed by 
immunoblot. GAPDH was used as a reference. C. LNT-229 cells were transfected 
with siRNA to a MMR family member or with scrambled control siRNA. Cells were 
assessed for MMR protein after 72 h by immunoblot. Control-transfected (black 
diamonds) or MMR knockdown (open squares) cells were exposed to increasing 
concentrations of TMZ for 24 h, 48 h after transfection, and allowed to grow 2-3 
weeks in FCS-containing medium (clonogenic assay). Cell density was assessed by 
crystal violet staining. Data in A and C are expressed as mean ± SEM (*p<0.05, 
**p<0.01, ***p<0.001, t-test). 
 
Figure 6. Altered histone H3 acetylation and methylation status in LNT-229_R 
cells. A. Global histone H3 expression (H3 total) (upper row) as well as expression of 
acetylated H3 (middle row) and trimethylated H3K9 (lower row) were assessed by 
immunoblotting in the parental and the resistant glioma cells (left panel). 
Corresponding quantitative analysis: right panel (black: parental cell line; white: 
resistant cell line). Immunoblot analysis for tubulin was used as loading control for 
normalization. B. Global DNA methylation levels as assessed by DNA 
pyrosequencing analysis of LINE-1 methylation levels (*p<0.05, t-test).  
 
 
 
 
 
